Nature Medicine: "No Longer Confident in Results' Integrity"
NYT Analysis: "China's Rise as a Drug Development Powerhouse Poses Threat to U.S."

A paper by a Chinese research team, which claimed that the timing of immunotherapy administration affects the survival period of lung cancer patients, was retracted just four months after its publication.


On the 26th, Yonhap News, citing the U.S. daily The New York Times (NYT), reported that the medical journal Nature Medicine had retracted a paper which claimed that administering immunotherapy to non-small cell lung cancer (NSCLC) patients in the morning or before 3 p.m. maximized its effectiveness. Nature Medicine stated, "We no longer have confidence in the integrity of the (research) results."

Notice of Retraction of Paper by Chinese Research Team. Nature Medicine Capture, Yonhap News

Notice of Retraction of Paper by Chinese Research Team. Nature Medicine Capture, Yonhap News

View original image

The issues with this research included the inability to prove a significant causal relationship in the team's claims, discrepancies between the original Chinese research plan and its English translation, and the fact that not a single patient dropped out of the study due to adverse effects. According to the NYT, most of the 28 authors of this study were based in China, with some co-researchers from Europe, and the research funding was provided by the Chinese government.


China has been investing heavily in hospitals and pharmaceutical companies to drive increases in patents, papers, and new clinical trials, rapidly emerging as a powerhouse in new drug development within just a few years. This is seen as a challenge to the new drug development dominance the United States has maintained for a long time. Against this backdrop, questions are frequently raised about the reliability of Chinese biomedical research, and the NYT pointed out that, just like in the United States, there are wide variations in the quality of research outcomes.


The paper, published in Nature Medicine in February of this year, previously claimed that administering immunotherapy in the early afternoon or morning, rather than late afternoon, nearly doubled the progression-free survival (PFS)—the period during which the cancer does not progress. The research team asserted that this was related to circadian rhythms, which cause metabolic functions to change depending on the time of day and night.


The study involved 210 patients with advanced non-small cell lung cancer at Hunan Cancer Hospital in China. Lung cancer is divided into small cell and non-small cell types based on the size of cancer cells, with non-small cell cases accounting for 80% of all patients. The patients were randomly assigned to receive the immunotherapy drug Keytruda (an American drug) or Tyvyt (a new drug not yet approved in the United States from China) either before or after 3 p.m. The progression-free survival (PFS) was about 11 months in the morning treatment group and about 6 months in the late afternoon group. Overall survival was also longer in the morning group (28 months) compared to the late afternoon group (17 months).


The paper sparked both skepticism and strong reactions as soon as it was released. Doctors reported being inundated with phone calls from patients wanting to switch their treatment times to the morning following the paper’s publication. However, some doctors and reviewers, particularly online, expressed strong doubts that simply shifting immunotherapy administration from the afternoon to the morning could nearly double survival periods.


Anil Makam, Professor of Medicine at the University of California, San Francisco, said, "If such dramatic results were true, we would have completely overhauled staffing and scheduling to adjust appointment times," adding, "If you believe in that effect, not making such changes could be considered medical malpractice."


About three weeks after publication, Nature Medicine announced it was conducting an investigation. At the European Lung Cancer Congress last March, research results analyzing data from about 3,000 lung cancer patients included in randomized clinical trials concluded that the timing of immunotherapy administration was unlikely to be a key factor in survival outcomes.



Unlike antipyretics or analgesics, immunotherapy does not produce immediate effects but remains in the body for an extended period, exerting its effects over several weeks. This supports the argument that simply changing the time of administration cannot explain differences in survival periods. However, the NYT noted that other studies have found a connection between the timing of immunotherapy and patient prognosis. Still, the specific reasons for these outcomes have not been clearly presented. Doctors explained that it is possible that patients who are more energetic and healthier tend to choose morning appointments, while low-income or rural patients may select afternoon appointments due to the time required to travel to the hospital.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing